Insider Transactions in Q3 2024 at Pliant Therapeutics, Inc. (PLRX)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 10
2024
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,319
-5.47%
|
$135,509
$11.56 P/Share
|
|
Jul 10
2024
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
9,900
-4.17%
|
$108,900
$11.56 P/Share
|
|
Jul 10
2024
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,911
-3.72%
|
$120,021
$11.56 P/Share
|
|
Jul 10
2024
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
38,710
-7.42%
|
$425,810
$11.56 P/Share
|
|
Jul 10
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
7,656
-7.53%
|
$84,216
$11.56 P/Share
|
|
Jul 09
2024
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,063
+9.65%
|
-
|
|
Jul 09
2024
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,337
+7.53%
|
-
|
|
Jul 09
2024
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,313
+6.78%
|
-
|
|
Jul 09
2024
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,625
+12.66%
|
-
|
|
Jul 09
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
14,954
+12.82%
|
-
|